{"id":"anaferon-for-children","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug contains highly diluted antibodies to human interferon gamma that are believed to act as an immune modulator, promoting the body's own interferon production and enhancing natural killer cell activity. It is used primarily in pediatric viral infections to support the immune system's antiviral defenses. The exact molecular mechanism remains incompletely characterized in conventional pharmacological terms.","oneSentence":"Anaferon for Children is an immunomodulatory agent that stimulates interferon production and enhances innate immune responses to combat viral infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:23:34.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute viral infections in children (influenza, ARVI, herpes simplex)"},{"name":"Prophylaxis of viral infections in pediatric patients"}]},"trialDetails":[{"nctId":"NCT03301155","phase":"PHASE4","title":"Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2017-10-03","conditions":"Preventive Medicine","enrollment":1036},{"nctId":"NCT02072174","phase":"PHASE4","title":"Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2014-10-08","conditions":"Influenza and Acute Respiratory Viral Infections","enrollment":569},{"nctId":"NCT03162458","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2015-01-22","conditions":"Acute Upper Respiratory Infections","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anaferon for Children in tablets"],"phase":"marketed","status":"active","brandName":"Anaferon for Children","genericName":"Anaferon for Children","companyName":"Materia Medica Holding","companyId":"materia-medica-holding","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anaferon for Children is an immunomodulatory agent that stimulates interferon production and enhances innate immune responses to combat viral infections. Used for Acute viral infections in children (influenza, ARVI, herpes simplex), Prophylaxis of viral infections in pediatric patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}